This chapter explores the controversies and debates surrounding gender medicine, specifically in the context of prescribing puberty blockers to children and adolescents. It delves into the tension between the affirmatory and exploratory approaches to treating gender dysphoria, as well as the concerns raised about the practical aspects of gender medicine services. The chapter also discusses the ethical considerations regarding conducting clinical trials for early intervention using puberty blockers.
Since its closure was announced last July, Gids — the Gender Identity Development Service at the world-renowned Tavistock and Portman Trust — has become synonymous with mismanagement and medical scandal.It was supposed to be a haven for young people experiencing gender-related distress. Instead, following a string of complaints by whistle-blowers, an “inadequate” rating by the Care Quality Commission, a high-profile judicial review and, finally, a damning independent review, it was deemed unsafe.In its place, two new regional hubs were set to open, with several more centres to follow. For Gids’s long-standing critics, concerned about the distress its tumult was having on children, this came as a huge relief.The story, however, does not end here.Kathleen Stock has spent the past month speaking to a range of clinicians, NHS professionals and parents of dysphoric children — to find out whether Gids’s new service will be an improvement.The portrait she paints is stark: her findings suggest that the NHS gender services are yet to become a clinically safe space for children and teens, with senior figures still pushing an activist ideology. Only last week, NHS bosses internally announced that they are significantly delaying the launch of one of the hubs. And as she reveals in her investigation, it is unlikely to be the final twist in Gids’s new chapter…
Hosted on Acast. See acast.com/privacy for more information.